Name: Iduronate 2-sulfatase (IDS) - BioCentury Target Profiles - BCIQ
Creator: Biocentury

Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Company Profiles
Target Profiles
Product Profiles

Explore BCIQ profiles by entering a target name.

REQUEST A FREE TRIAL

BioCentury | Feb 21, 2024

Product Development

Clinical report: Latest setback in RIPK1 program for Denali, Sanofi

Plus: RAPT’s clinical hold, Tagrisso’s latest readout

BioCentury | Mar 18, 2022

Finance

Precirix building out radiotherapy platform with €80M series B

The Belgian company is branching out into alpha emitters and growing its geographical footprint

BioCentury | Jul 27, 2021

Product Development

July 26 Quick Takes: Denali dips on Hunter syndrome readout

Plus: GSK, BMS, PerkinElmer-BioLegend and more

BioCentury | Feb 13, 2021

Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

Shares of G1 Therapeutics Inc. (NASDAQ:GTHX) rose 20% to $37.15 in after-hours trading after FDA approved Cosela trilaciclib to decrease bone marrow suppression caused by chemotherapy in adults

BioCentury | Nov 14, 2020

Product Development

Denali holds gains after first human proof of concept for brain delivery tech

Denali this week reported the first clinical proof-of-concept data from its transport vehicle (TV) technology, which shuttles large molecules across the blood-brain barrier, pushing its shares to

BioCentury | Aug 7, 2020

Deals